/ATNM
ATNM Stock - Actinium Pharmaceuticals, Inc.
Healthcare|BiotechnologyAMEX
$1.69+6.29%
+$0.10 (+6.29%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.79
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+555.0%upside
Target: $11.07
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATNM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.67 – $1.71
TARGET (TP)$11.07
STOP LOSS$1.55
RISK/REWARD1:67.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.36
52W High$2.41
52W Low$1.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $81,000 | $1.03M | $1.14M | N/A |
| Gross Profit | $-811,000 | $81,000 | $1.03M | $620,000 | $-447,000 |
| Gross Margin | N/A | 100.0% | 100.0% | 54.2% | N/A |
| Operating Income | $-42,121,000 | $-51,920,000 | $-34,104,000 | $-24,964,000 | $-22,393,000 |
| Net Income | $-38,243,000 | $-48,818,000 | $-33,017,000 | $-24,774,000 | $-22,215,000 |
| Net Margin | N/A | -60269.1% | -3205.5% | -2165.6% | N/A |
| EPS | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 |
Company Overview
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 782.8% Upside
Now
$2
Low
$15
Average
$25
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 7th 2024 | B. Riley Securities | Downgrade | Neutral | $2← $16 |
| May 14th 2024 | Stephens | Initiation | Overweight | $25 |
| September 6th 2023 | HSBC Securities | Initiation | Buy | $11.6 |
| February 21st 2023 | William Blair | Downgrade | Market Perform | - |
| September 8th 2022 | Cantor Fitzgerald | Initiation | Overweight | $20 |
| August 25th 2022 | B. Riley Securities | Initiation | Buy | $16 |
Earnings History & Surprises
ATNMBeat Rate
47%
Last 19 quarters
Avg Surprise
-1.5%
EPS vs Estimate
Beats / Misses
9/9
1 met exactly
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+38.9%
$-0.33vs$-0.54
Q2 24
+26.2%
$-0.31vs$-0.42
Q3 24
+20.8%
$-0.38vs$-0.48
Q4 24
-5.7%
$-0.37vs$-0.35
Q1 25
+43.2%
$-0.21vs$-0.37
Q2 25
-96.2%
$-0.51vs$-0.26
Q3 25
+31.3%
$-0.22vs$-0.32
Q4 25
+36.0%
$-0.16vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.32 | $-0.22 | +31.3% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-0.26 | $-0.51 | -96.2% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.37 | $-0.21 | +43.2% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q3 2024 | Aug 5, 2024 | $-0.48 | $-0.38 | +20.8% | ✓ BEAT |
Q2 2024 | Apr 26, 2024 | $-0.42 | $-0.31 | +26.2% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | $-0.54 | $-0.33 | +38.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.53 | $-0.49 | +7.5% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.50 | $-0.58 | -16.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.42 | $-0.43 | -2.4% | ✗ MISS |
Q2 2023 | Apr 3, 2023 | $-0.26 | $-0.42 | -61.5% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.30 | $-0.38 | -26.7% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.23 | $-0.33 | -43.5% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-0.31 | $-0.23 | +25.8% | ✓ BEAT |
Q1 2022 | Mar 25, 2022 | $-0.30 | $-0.36 | -20.0% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.29 | $-0.30 | -3.4% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | $-0.30 | $-0.25 | +16.7% | ✓ BEAT |
Q2 2021 | May 14, 2021 | $-0.29 | $-0.29 | 0.0% | = MET |
Latest News
Cellectar Biosciences Announces Multi-Year Supply Agreement With Ionetix For Actinium-225 And Astatine-211
📈 PositiveBenzinga•Dec 16, 2025, 01:08 PM•Also:
Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B7-H3
📈 PositiveBenzinga•Dec 8, 2025, 07:48 PM
Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025
📈 PositiveBenzinga•Dec 1, 2025, 01:49 PM
Actinium To Present New Breast Cancer Data On Its ATNM-400 Radiotherapy At San Antonio Symposium
📈 PositiveBenzinga•Nov 4, 2025, 12:34 PM
Actinium Pharma Presents Preclinical Data Of ATNM-400 In Non-Small Cell Lung Cancer At AACR-NCI-EORTC International Conference
➖ NeutralBenzinga•Oct 27, 2025, 11:17 AM
Actinium Pharmaceuticals are trading higher. The company presented new preclinical data for ATNM-400 antibody radioconjugate at 32nd annual Prostate Cancer Foundation scientific retreat in Carlsbad, California.
📈 PositiveBenzinga•Oct 24, 2025, 06:10 PM
Actinium Pharmaceuticals Presents New Preclinical Data For ATNM-400 Antibody Radioconjugate At 32nd Annual Prostate Cancer Foundation Scientific Retreat In Carlsbad, California
📈 PositiveBenzinga•Oct 24, 2025, 12:31 PM
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
📈 PositiveBenzinga•Oct 14, 2025, 12:37 PM•Also:
Actinium Pharmaceuticals Announces That The First-Ever Preclinical Data From Its ATNM-400 Program In Non-Small Cell Lung Cancer Has Been Accepted For Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Being Held October 22 – 26, 2025
📈 PositiveBenzinga•Oct 13, 2025, 04:14 PM
Frequently Asked Questions about ATNM
What is ATNM's current stock price?
Actinium Pharmaceuticals, Inc. (ATNM) is currently trading at $1.69 per share. The stock has moved +6.29% today.
What is the analyst price target for ATNM?
The average analyst price target for ATNM is $11.07, based on 1 analyst.
What sector is Actinium Pharmaceuticals, Inc. in?
Actinium Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is ATNM's market cap?
Actinium Pharmaceuticals, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does ATNM pay dividends?
No, Actinium Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to ATNM for comparison